InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient ...
We got aggressive with some trades in a new 2027 NFL Mock Draft as we get ready for training camp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results